Lokavant, a NYC-based clinical trial intelligence platform company, raised $8M in funding.
The round, which brought the total amount to $29M, saw participation from Mitsui & Co, Edison Partners and Roivant Sciences (Nasdaq: ROIV).
The company intends to use the funds to expand the adoption of its AI-optimized platform across the Asia-Pacific (APAC) region. Lokavant is to open a new APAC headquarters in Tokyo.
Led by CEO Rohit Nambisan, Lokavant provides clinical trial teams with an intelligence platform that improves the time, cost, and quality of trial planning and execution through data-driven analytics solutions. Leveraging a proprietary data asset of historical trial data from more than 2,000 studies involving more than 14,000 investigators, 12,000 healthcare institutions, and integrated real-world data (RWD) sources, the platform and analytical applications help pharmaceutical companies increase the accuracy and efficiency of trial planning and execution. Its Clinical Trial Intelligence Platform provides sponsors and CROs with real-time, predictive analytics in a continuous feedback loop.
Customers include CMIC Group.
FinSMEs
05/10/2023